Researchers at the National Institutes of Health (NIH) have uncovered new details about how GLP-1 receptor agonists, a class of drugs used for weight loss and diabetes, affect brain cells at the molecular level. The study, conducted in mice and published in the journal Science on May 22, 2026, identified specific intracellular signaling pathways activated by these drugs within neurons, which had been largely unexplored.
The team, led by Dr. Michael Krashes at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), used advanced imaging techniques to track the effects of semaglutide, a common GLP-1 receptor agonist, on mouse brain cells. They found that the drug triggers a cascade of events inside neurons, including the activation of the protein kinase A (PKA) pathway, which influences appetite regulation and energy balance.
“This is the first time we’ve seen the precise intracellular changes that GLP-1 drugs cause in neurons,” said Dr. Krashes in an NIH press release. “Understanding these mechanisms could lead to more targeted therapies with fewer side effects.” The study focused on neurons in the hypothalamus, a brain region critical for controlling hunger and metabolism.
The findings are significant because GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy), have become widely used for weight management, but their exact effects on the brain have remained unclear. The NIH research suggests that these drugs not only act on peripheral organs but also directly alter brain cell function, which may explain their effectiveness in reducing appetite.
Experts caution that the study was conducted in mice and further research is needed to confirm the findings in humans. The NIH plans to expand the research to human brain tissue samples in the coming months. The study was funded by the NIDDK and the NIH Intramural Research Program.
